Shandong Boan Biotechnology Announces Major New Indication Approval for Boluojia® (Denosumab Injection) in China
Key Points and Investor Highlights
- Regulatory Milestone: China’s National Medical Products Administration (NMPA) has granted approval for Boluojia® (denosumab injection 120 mg) for the treatment of bone metastases from solid tumors and multiple myeloma. This expands the drug’s approved indications beyond its initial May 2024 approval for giant cell tumor of bone (GCTB).
- Market Opportunity: Bone metastasis is a major complication in cancer care, with over 80% originating from breast, prostate, lung, thyroid, and kidney cancers. Multiple myeloma patients are also highly affected, with 80% developing myeloma bone disease—a significant unmet medical need.
- Product Profile: Boluojia® is a biosimilar of Xgeva®, developed independently by Boan, and is not subject to renal clearance, enabling safe use in patients with renal impairment. It is administered via subcutaneous injection, adding convenience for patients.
- Clinical Evidence: Robust clinical data supports Boluojia®, including pivotal studies published in the Journal of Bone Oncology and a Phase III trial presented at ASCO 2023. Boluojia® is recommended as a first-line therapy by ESMO, NCCN, and CSCO guidelines.
- Global Expansion: Boan has completed an international multicenter Phase III trial in Europe, the U.S., and Japan. The UK marketing authorization application is under review, and filings are planned for the U.S., EU, Japan, and other high-potential markets.
- Commercial Strategy: Boan uses a dual approach—direct sales in China (with a network covering 3,000+ hospitals) and strategic partnerships overseas. Agreements include Nanjing King-Friend Biochemical Pharmaceutical (NKF) for the U.S., Shanghai Pharmaceutical (Shaphar) for Southeast Asia, and PHARMACARE for Latin America.
- Financial Implications: Global sales of Xgeva® in 2025 reached USD 2.084 billion, with China contributing USD 306 million (up 36.4% YoY from 2024). Boluojia® is well-positioned to capture part of this high-growth market, potentially impacting Boan’s revenue and share value.
- Leadership and Corporate Governance: The announcement is signed by Chairlady, CEO, and Executive Director Jiang Hua, reflecting strong leadership and governance.
Detailed Analysis for Investors
Shandong Boan Biotechnology’s latest regulatory achievement is a significant catalyst for the company’s valuation. The approval of Boluojia® for bone metastases from solid tumors and multiple myeloma addresses a critical and high-prevalence need in oncology. With bone metastasis being a frequent and severe complication in major cancers, the expanded indication opens up access to a large patient population.
Boluojia®’s biosimilarity to Xgeva® and its favorable administration profile (no renal clearance, subcutaneous injection) positions it competitively against existing therapies. The robust clinical evidence and guideline recommendations reinforce its acceptance as a standard of care, supporting rapid adoption.
The company’s commercial strategy leverages both in-house capabilities and partnerships to maximize global reach. The completion of international Phase III trials and ongoing regulatory filings in key markets such as the U.K., U.S., EU, and Japan suggest substantial revenue potential and international recognition.
Financially, Boan stands to benefit from a large and fast-growing market. With Xgeva®’s sales demonstrating strong growth in China and globally, Boluojia® could drive substantial revenue increases, especially as it complements Boan’s oncology portfolio and strengthens its market presence.
For shareholders, this announcement is highly price-sensitive. Regulatory approvals, expansion into new indications, and global commercialization efforts typically act as major share price movers, particularly when backed by strong clinical and financial data.
Potential Impact on Shareholders
- Revenue Growth: Expanded indications and global launch plans could significantly boost sales and profits.
- Market Position: Boluojia® strengthens Boan’s oncology portfolio and competitive edge.
- Global Footprint: International partnerships and regulatory submissions herald broader market access.
- Share Price Sensitivity: The news is likely to be viewed positively by investors and could move Boan’s share price.
Disclaimer
The above article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The announcement contains forward-looking statements regarding future performance and regulatory outcomes, which carry risks and uncertainties.
廣東話版本
山東博安生物科技宣佈博羅佳®（地舒單抗注射液）新適應症獲中國批准
重點及投資者須知
- 監管里程碑：中國國家藥品監督管理局（NMPA）批准博羅佳®（地舒單抗注射液120mg）用於治療實體腫瘤骨轉移及多發性骨髓瘤，擴大了該藥自2024年5月獲批治療巨大細胞骨瘤（GCTB）以來的適應症。
- 市場機遇：骨轉移是癌症治療常見且嚴重併發症，超過八成來自乳腺、前列腺、肺、甲狀腺及腎癌。多發性骨髓瘤患者中八成會發生骨病，屬重大未滿足需求。
- 產品特點：博羅佳®為Xgeva®的生物類似藥，由博安自主研發，不經腎臟排泄，適合腎功能受損患者，並以皮下注射，方便用藥。
- 臨床證據：博羅佳®臨床數據穩健，關鍵研究已發表於《骨腫瘤學雜誌》，III期試驗於2023年ASCO會議展示。獲ESMO、NCCN及CSCO指引推薦為一線治療。
- 全球拓展：國際多中心III期試驗已完成，英國申請上市許可正在審批，並計劃向美國、歐盟、日本及其他高潛力市場申報。
- 商業策略：博安採用自主銷售及合作雙管齊下，中國覆蓋逾3,000家醫療機構，海外授權南京健友（NKF）於美國推廣、與上藥於東南亞、PHARMACARE於拉美推廣。
- 財務影響：Xgeva®於2025年全球銷售達20.84億美元，中國佔3.06億（較2024年增長36.4%）。博羅佳®有望分得此高增長市場，帶來收入及股價提升。
- 領導及管治：董事會主席、CEO及執行董事江華簽發公告，反映公司領導穩健。
詳細投資者分析
博安生物此次監管突破是公司估值的重大催化劑。博羅佳®新適應症獲批，針對腫瘤骨轉移及多發性骨髓瘤的龐大患者群，開拓了更大市場。其生物類似性、便捷用藥及臨床證據，令其具競爭力，預期快速滲透市場。
商業策略及國際拓展，將帶來收入增長及全球認可。與Xgeva®銷售數據比較，博羅佳®有望帶來可觀財務回報。對股東而言，此消息屬敏感，或會推動股價上升。
對股東的潛在影響
- 收入增長：新適應症及全球上市計劃將顯著提升銷售及盈利。
- 市場地位：博羅佳®強化博安腫瘤產品線及競爭優勢。
- 全球布局：海外合作及監管申報意味更廣市場。
- 股價敏感：消息屬重大利好，或推動股價上升。
免責聲明
本文章僅供參考，並不構成投資建議。投資者應自行做好盡職調查，並諮詢財務顧問。公告包含前瞻性陳述，存在風險及不確定性。
